Suppr超能文献

非肝硬化性肝细胞癌:源自肝细胞腺瘤?临床病理分析。

Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis.

机构信息

Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.

Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.

出版信息

Mod Pathol. 2014 Mar;27(3):420-32. doi: 10.1038/modpathol.2013.148. Epub 2013 Sep 20.

Abstract

The majority of hepatocellular carcinomas arise in background chronic liver disease, particularly cirrhosis. The pathogenesis of noncirrhotic hepatocellular carcinomas remains unclear. While malignant transformation reportedly occurs in <15% of hepatocellular adenoma, the prevalence of noncirrhotic hepatocellular carcinomas arising from a pre-existing adenoma is a challenge to study. Cirrhotic hepatocellular carcinoma and hepatocellular adenoma may be subclassified by molecular pathways, but little is known in noncirrhotic hepatocellular carcinoma. We aim to delineate clinical, morphologic and immunohistochemical features of noncirrhotic hepatocellular carcinoma to evaluate for possible derivation from hepatocellular adenoma. We evaluated the clinicopathologic features of 74 noncirrhotic hepatocellular carcinomas from 72 patients for underlying clinical conditions and immunohistochemical markers known to be associated with hepatocellular adenoma. Men were more commonly affected (59%); however, in the <50-year-old group, women predominated (8:1). The age range was wide: 18-83 years; median-64 years. Underlying liver diseases were identified in only 7%; however, 25% had diabetes mellitus, 69% were overweight or obese and 58% had metabolic syndrome. Only 50% of the noncirrhotic hepatocellular carcinoma were encapsulated. As published in hepatocellular adenoma, multifocality and larger tumor size were more common in liver fatty acid-binding protein-negative noncirrhotic hepatocellular carcinoma. Beta-catenin nuclear positivity was uncommon (5%), and was restricted to hepatocellular carcinomas in older men. Serum amyloid A positivity was not restricted to any subtype. In summary, we present the largest series to date examining noncirrhotic hepatocellular carcinoma. We evaluated these with current hepatocellular adenoma subclassification markers for possible associations. Thirty percent of the 74 noncirrhotic hepatocellular carcinoma had some clinical, morphological or immunophenotypical associations currently described in hepatocellular adenoma. Our data also confirm the association of noncirrhotic hepatocellular carcinoma in middle-aged to elderly men, an association with metabolic syndrome, and, as with hepatocellular adenoma, that women predominated in the noncirrhotic hepatocellular carcinoma subjects <50 years of age.

摘要

大多数肝细胞癌发生在慢性肝病背景下,尤其是肝硬化。非肝硬化性肝细胞癌的发病机制仍不清楚。虽然据报道肝细胞腺瘤中恶性转化发生率<15%,但从先前存在的腺瘤中发生非肝硬化性肝细胞癌的患病率是一个具有挑战性的研究课题。肝硬化性肝细胞癌和肝细胞腺瘤可通过分子途径进行分类,但在非肝硬化性肝细胞癌中知之甚少。我们旨在描绘非肝硬化性肝细胞癌的临床、形态学和免疫组织化学特征,以评估其是否可能来源于肝细胞腺瘤。我们评估了 72 例患者的 74 例非肝硬化性肝细胞癌的临床病理特征,以评估与肝细胞腺瘤相关的潜在临床情况和免疫组织化学标志物。男性更常见(59%);然而,在<50 岁的患者中,女性占主导地位(8:1)。年龄范围很广:18-83 岁;中位数-64 岁。仅在 7%的患者中确定了基础肝病;然而,25%患有糖尿病,69%超重或肥胖,58%患有代谢综合征。只有 50%的非肝硬化性肝细胞癌有包膜。如在肝细胞腺瘤中报道的那样,在肝脏脂肪酸结合蛋白阴性的非肝硬化性肝细胞癌中,多灶性和更大的肿瘤大小更为常见。贝塔连环蛋白核阳性并不常见(5%),仅限于老年男性的肝细胞癌。血清淀粉样蛋白 A 阳性不受任何亚型限制。总之,我们目前展示了迄今为止最大的非肝硬化性肝细胞癌系列研究。我们用目前的肝细胞腺瘤亚分类标志物评估这些标志物,以确定可能的关联。74 例非肝硬化性肝细胞癌中有 30%具有目前在肝细胞腺瘤中描述的某些临床、形态学或免疫表型关联。我们的数据还证实了非肝硬化性肝细胞癌在中年至老年男性中的关联,与代谢综合征的关联,以及与肝细胞腺瘤一样,在<50 岁的非肝硬化性肝细胞癌患者中女性占主导地位。

相似文献

1
Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis.
Mod Pathol. 2014 Mar;27(3):420-32. doi: 10.1038/modpathol.2013.148. Epub 2013 Sep 20.
3
A Limited Immunohistochemical Panel Can Subtype Hepatocellular Adenomas for Routine Practice.
Am J Clin Pathol. 2017 Jun 1;147(6):557-570. doi: 10.1093/ajcp/aqx010.
5
[Hepatocellular tumours in noncirrhotic liver tissue].
Pathologe. 2015 Nov;36(6):597-606; quiz 607-8. doi: 10.1007/s00292-015-0113-0.
6
Expression of liver fatty acid binding protein in hepatocellular carcinoma.
Hum Pathol. 2016 Apr;50:135-9. doi: 10.1016/j.humpath.2015.12.002. Epub 2015 Dec 18.

引用本文的文献

1
What should be the best approach post-liver resection in non-viral non-cirrhotic hepatocellular carcinoma?
Hepatobiliary Surg Nutr. 2024 Jun 1;13(3):554-556. doi: 10.21037/hbsn-24-132. Epub 2024 May 24.
2
Hepatocellular Carcinoma in a Free-Ranging Three-Toed Sloth ().
Animals (Basel). 2022 Jul 28;12(15):1921. doi: 10.3390/ani12151921.
3
Malignant transformation of hepatocellular adenoma.
JHEP Rep. 2022 Jan 7;4(3):100430. doi: 10.1016/j.jhepr.2022.100430. eCollection 2022 Mar.
5
Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model.
PLoS One. 2019 Feb 22;14(2):e0212860. doi: 10.1371/journal.pone.0212860. eCollection 2019.
6
Malignant transformation of hepatocellular adenoma.
Hepat Oncol. 2014 Oct;1(4):421-431. doi: 10.2217/hep.14.14. Epub 2014 Dec 11.
7
The Natural Course of Non-Alcoholic Fatty Liver Disease.
Int J Mol Sci. 2016 May 20;17(5):774. doi: 10.3390/ijms17050774.

本文引用的文献

2
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.
J Exp Med. 2011 Jul 4;208(7):1359-66. doi: 10.1084/jem.20110283. Epub 2011 Jun 20.
3
Hepatocellular carcinoma: screening and staging.
Clin Liver Dis. 2011 May;15(2):323-34, vii-x. doi: 10.1016/j.cld.2011.03.003.
4
Depicting the role of TP53 in hepatocellular carcinoma progression.
J Hepatol. 2011 Sep;55(3):724-725. doi: 10.1016/j.jhep.2011.03.018. Epub 2011 May 14.
5
Management of hepatocellular carcinoma: an update.
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
6
Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers.
Semin Liver Dis. 2011 Feb;31(1):91-103. doi: 10.1055/s-0031-1272837. Epub 2011 Feb 22.
7
Changing trends in malignant transformation of hepatocellular adenoma.
Gut. 2011 Jan;60(1):85-9. doi: 10.1136/gut.2010.222109.
9
Population-based risk factors and resource utilization for HCC: US perspective.
Curr Med Res Opin. 2010 Sep;26(9):2183-91. doi: 10.1185/03007995.2010.506375.
10
Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
Hepatology. 2010 May;51(5):1820-32. doi: 10.1002/hep.23594.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验